Replies to post #89752 on Biotech Values

[DewDiligence]

ACHN’s mention of the NS3 target in the latest PR may mean that ACH-2684 is a helicase inhibitor—or a combination helicase/protease inhibitor. If so, this is not a unique MoA; for instance, BMY’s BMS-650032 is such a compound.